Thanks, Bill.
of and which TABX, And profile tuspetinib handful can and kinase dosing. JAKX oral with by oncogenic that often X, wild-type patients also but and created relapse. suppress treat with Let background multiple with of molecule, me myeloid lead maintains myelosuppression tuspetinib key KIT to mutant several tuspetinib. as and oncogenic favorable RSKX relative you giving not and said patient start FLTX, kinases the persistent noteworthy the kinase, X even AML that SYK This targeting safety safety disease no AML. to a as forms, forms By prolonged superior safety profile once-daily, other drugs. all in factor differentiating I be major underestimated this TAKX forms cannot importance inhibitor on pathways, profile the drive was a some is of before, suppresses population. a Tuspetinib's and Yet importantly, pathways progression highly a vulnerable to
After held we escalation trial successful extensive earlier, recommended our dose dose dose End completing with patients, and with over data, with the a to Rice After the Dr. once findings FDA treatment FDA. dose presented an we for daily Phase AML meeting the of the selected patients XX of exploration II As mentioned Phase monotherapy review of as tuspetinib. an was XX-milligram I tuspetinib. for
addition, metabolite with in way, including In to required. paths And monitoring development tuspetinib dose the going or confirmed remain XX-milligram the FDA that be accelerated venetoclax. by that path monotherapy the is being now all single-arm QTc no as were the special and studies level and with used combination open,
is trial the and to clinical tuspetinib and information what patients, APTIVATE with exploration talk AML the as trial us a relapsed/refractory from we perspective. seeing initiated a or the doublet XX relapsed/refractory dose therapy trial tuspetinib Phase Phase happy with patients. as I'm that in Following about dose with escalation of tuspetinib leading where a extension completion development we're successful in monotherapy I/II APTIVATE AML I/II in
know, trial, clinical APTIVATE and is and X our up trial, a with running This has across being the now globe, you we As administered U.S., team in have global Europe. where is Australia, including venetoclax. a and arm and the Korea, sites combination numerous in U.K. monotherapy arms: tuspetinib therapy sites expansion a in cohort
study that sites of including in Australia first venetoclax soon. enrolling Enrollment in failed Spain treatment. we antileukemic we patient had preliminary our and quarter in in the brisk and countries response very with we June, highlight have brisk provided highlighted enrollment, year. the We poised be expansion arm already that already a doublet our as to EHA complete expand continues in trial internationally this a had activity, newly further to During additional noted a we APTIVATE TUS/VEN begin activated and initiated
in enrolled had TUS the XX X, we AML in August arm patients TUS/VEN arm. and XXXX, of relapsed/refractory monotherapy APTIVATE the in the As XX study, XX doublet
in evaluable number there patients of A also patients less X failed had the date, monotherapy the patients monotherapy were response efficacy and venetoclax observed was that arm TUS treated been reached who quickly in monotherapy, responsive earlier in we had venetoclax. previously cohorts. of As X prior stage, the arm and a that to therapy the on progressed with pattern
received evaluable our preliminary response assessments doublet In contrast, findings TUS/VEN TUS/VEN you the of the and through meaning very they XX sufficient undergone XX on therapy We're arm and the reached stage, doublet in had the of efficacy arm. patients had findings with doublet the these appropriate I had already now. walk pleased in arm, want to some
a the as inclusive have partial of incomplete seen with recovery leukemia-free TUS/VEN CRc, morphologic evaluable this today complete a is on study or we doublet or defined thunder a are may CRis Bill out in combination platelet remissions, While that remissions XX%. rate, response far, with -- And complete of This bit the of recovery hematologic our a or we've of recovery. stolen my complete hematologic state. report the little patients XX cautionary appropriate comments, composite here of complete and thus
is venetoclax were often conversations population. with This all in of patients investigator prior failure. relapsed/refractory X yields a rate of These in data therapy. the therapies venetoclax And desperate clones to evaluable fail patients had resistant ill treat acquire prior with highly growing Considering we results. to refractory failed overall a prior that venetoclax venetoclax population XX XX% need X therapy the publications these who AML patients that the expand failure salvage with towards effective positive failure responses have in of that registrational salvage this of and among response this TUS/VEN effectively doublet out venetoclax excited highlighted treatments, therapies. see X or salvage were are responses. achieving prior an point to Recent our scarcity is very trial population, these of
with with response for the emerge the among unmutated account XX% evaluable there X AML of overall doublet, responses for XX X FLTX population, TUS/VEN yet rate. with patients XX% received Also, Patients options who significantly are among of an patients FLTX approximately unmutated is tuspetinib. FLTX this for feature of the The treat And development differentiating treatment tuspetinib this drug. unmutated market patients an few extends ability patient and to important a little this for in population. potential
there patients were we to observed X an responses date, the overall response In in the doublet few patients while trial albeit for X of addition, FLTX-mutated in XX%, of TUS/VEN evaluable numbers. rate small
against One of the forms highlighting have a FLTX-ITD with with treated highly we activity mutation other the the in X responders in a and kinase are drug domain, tyrosine of albeit right in harbored FLTX. mutation this this the doublet the far, the Thus again, observed the patient the response and harbored small of a numbers mutants gene, evaluable a broad mutation TPXX direction. adverse numbers, in in trending trial TUS/VEN very patient, we
need. patients may great these ability to a have have monotherapy the these than and as trial mentioned of patients unmet All even path might. we And a medical quicker allow a before, registration clearer to us rescue
and tolerability with Tuspetinib Another could therapeutic profile, own be its its can side differentiator date. ideal use. favorable have well is an the to effects a doublet limit safety to venetoclax, even in to tuspetinib's TUS/VEN prove drug combine that noteworthy prolonged may that
of our in a them option treatment meaningful the study for their an the earlier physicians, last clinical and increasing represents patients and to call of leading attractive in I mentioned treatment enroll benefit. likelihood that the APTIVATE achieving course
has first doublet. accrual focus heavily Several TUS/VEN with rapid more brisk who XXXX, the more enrollment as of on are result, drove half continues factors doublet. heavily become to the have on this during a enrollment As focused been decision we the and patients TUS/VEN of
once-daily safety models combine favorable in profile synergistically and vivo preclinical AML. And highly that First, TUS/VEN as a as a tuspetinib in of we second, know tablet. has convenient
for indicate drug-resistant creates AML lethality an is tuspetinib combination cells, in resistance drug that ideal drug that addition, venetoclax induction In for supporting studies therapy. the tuspetinib synthetic in idea vitro partner
need the because treated and patients they become with once venetoclax board advisory Furthermore, advisers they an a rapidly highly emerging to AML see drug, refractory this therapy. salvage in fail
this data including they difficult-to-treat this very doublet a FLTX, unmutated highly activity TPXX, MLL, against after broad adverse with TUS/VEN of Because doublet failure doublet mutated mutations, Data more AML, maturing, is serve range highlights FLTX prior broad of guide available. shown that exhausted unmutated the but has mutated are and if of deliver trial patients. FLTX, in suggest the TUS mutated can therapeutic population mutated venetoclax, TUS/VEN are AML this Our responses activity much meaningful breadth RAS believe still can second-line population. both mutated venetoclax-exposed patients any, we a TUS/VEN This their venetoclax or again, illustrating in registrational approved who have failure, prior third-line AML toward randomized patients with FLTX than doublet and a TUS/VEN from with inhibitor. us options, in tuspetinib
would an their deliver be an by recommended build may this trial a needs for of with type while data being trial upon Advisory to would early Board. provide This the models, Daver was partners the data. of of maturity powered approval potential continued accelerated commercial AML of Dr. for to recognizing This full assessment population. value the and tuspetinib, approval our It in Clinical significant serve
needed a provide of as understanding TUS/VEN In collection a doublet data apply AML of triplet in patients. the to frontline tuspetinib part study addition, TUS/VEN/HMA with can
have that FLTX, our agents. achieving VEN/HMA addition prolonged that Daver carrier with can tuspetinib patients Dr. create of without is therapies and at to great broadly the be his by at to the towards The recently merely is that with success mutation agents. some toxicities only a the mutated MD it combination done cardiotoxicity doublet caused to be each be triplet its that brought additional published in doublet applied mix We as combination unmutated shifting addition limited and and can FLTX of treating not by lead XX% in envisioned or triplet the therapies, are AML competing strong diagnosis these of by can the into AML safety mylosuppression and profile paradigm of for investigator, quickly Anderson know team
as about talk So tuspetinib now briefly monotherapy. let's
the as I/II During X responses multiple emerging levels across trial, tuspetinib and of in monotherapy with completed APTIVATE monotherapy with and totality activity in It our CRc tuspetinib disease relapsed/refractory broad no clearly have about of active in delivered date escalation escalation expansion diverse The even population. genotypes, is TPXX. dose RAS including and mutations from and mutationally has and our AML our talked includes recently unmutated the range those a well as the Phase trial lot in the of exploration both single-agent other a presence dose patient tuspetinib. trial adverse across data DLTs to AML from dose dose the as difficult-to-treat such and and pathway of with mutated
tuspetinib We've our with in previously less activity as patients in salvage patients impressive also will available. seen learned ongoing second more have therapies Since other AML activity of any the expect therapy. the being might we patients. that venetoclax, clear is more are venetoclax with one setting venetoclax with and first even we and in began, combination later activity for in already AML pretreated even Therefore, study or treated when focus are where line in treated efforts off-label, on and approved venetoclax our frontline
MDS, with second venetoclax. as well test genetic as a would tuspetinib. monotherapy we AML patients we through with have as XXXX, well tuspetinib with in include number with the tuspetinib This features proceed in unmutated patients plan treatment As and to to MDS-like of of combination half responded FLTX
in have a earnings next our call. lot will MDS on more We
a its larger tuspetinib combination towards. in working ultimately in we're what allow and The specific much profile with that's guided activity data term. the it may the market, candidate for populations us make with to near the frontline, tuspetinib's approval broad have But date that collected therapy addressing to ideal accelerated safety
most clear be that trials most commercialization to tuspetinib, would these of currently to great signal select interest [ to approvals potential of partners. we we for and in fastest have -- accrual, earliest that provide do collect ] development task will the the resources will not While all interesting help pursue the and data
biotech as of the that, with drug Rice pharma a we discussions Having because partners has mentioned number biotech earlier, the of capacity small large the are meet fully needs regulatory needs meet market Dr. the large partners. our we potential owner Therefore, exploit accruals of capabilities ] potential a needs adjust Aptose, of agencies tuspetinib to looks to to [ patient potential. a in like its or and may said meet that and maybe
tuspetinib in So our plans, its the superior ultimately breadth activity AML may market safety we most are summarize to of proven that sizable clinical with address and profile developing as such.
First, trial the failed therapy, us a TUS/VEN emerging approval guiding target to with who data are patients to and unmet need. registrational doublet a great the for venetoclax with accelerated AML medical have population
triple We trial will expect registrational inform additional use combinations this for in for in as in setting therapies and well. the trials finally, therapy the data frontline maintenance use from
we sum is when APTIVATE let me at So forums. open-label will report appropriate available Because trial, up. an data
arm As and European at we October updated from we discussed TUS/VEN meeting, expanded data in an our more Haematology ASH in plan of data or set, doublet the December. particularly then the meeting at the even School last call, in be clinical present ESH,, to to
calls. Bill with And registrational Plus, any year, will at data tuspetinib. present we additional expect with call, we color earnings as this fourth of findings quarter mature the around Meeting, Also, earlier, additional plans and more material during we interim may earnings release provide time our during around during November, these mentioned conferences to updates. In ASH the plan to tuspetinib. in December provide Annual clinical we the then
the forward coming in months. Stay a tuned. So look to we lot to have
to Now like an the Payne, I'd Fletcher update on over turn our to CFO, Fletcher? call our status. financial for
